FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953732145> ?p ?o ?g. }

• W2953732145 endingPage "449" @default.
• W2953732145 startingPage "444" @default.
• W2953732145 abstract "Despite the use of vidarabine, herpes simplex virus (HSV) infection in neonates continues to be a disease of high morbidity and mortality. We undertook a controlled trial comparing vidarabine with acyclovir for the treatment of neonatal HSV infection.Babies less than one month of age with virologically confirmed HSV infection were randomly and blindly assigned to receive either intravenous vidarabine (30 mg per kilogram of body weight per day; n = 95) or acyclovir (30 mg per kilogram per day; n = 107) for 10 days. Actuarial rates of mortality and morbidity among the survivors after one year were compared overall and according to the extent of the disease at entry into the study (infection confined to the skin, eyes, or mouth; encephalitis; or disseminated disease).After adjustment for differences between groups in the extent of disease, there was no difference between vidarabine and acyclovir in either morbidity (P = 0.83) or mortality (P = 0.27). None of the 85 babies with disease confined to the skin, eyes, or mouth died. Of the 31 babies in this group who were treated with vidarabine and followed for a year, 88 percent (22 of 25) were judged to be developing normally after one year, as compared with 98 percent (45 of 46) of the 54 treated with acyclovir (95 percent confidence interval for the difference, -4 to 24). For the 71 babies with encephalitis, mortality was 14 percent with vidarabine (5 of 36) and with acyclovir (5 of 35); of the survivors, 43 percent (13 of 30) and 29 percent (8 of 28), respectively, were developing normally after one year (95 percent confidence interval for the difference, -11 to 39). For the 46 babies with disseminated disease, mortality was 50 percent (14 of 28) with vidarabine and 61 percent (11 of 18) with acyclovir (95 percent confidence interval for the difference, -20 to 40); of the survivors, 58 percent (7 of 12) and 60 percent (3 of 5), respectively, were judged to be developing normally after one year (95 percent confidence interval for the difference, -40 to 50). Both medications were without serious toxic effects.In this multicenter, randomized, blinded study there were no differences in outcome between vidarabine and acyclovir in the treatment of neonatal HSV infection. The study lacked statistical power to determine whether there were sizable differences within the subgroups of those with localized HSV, encephalitis, or disseminated disease." @default.
• W2953732145 created "2019-07-12" @default.
• W2953732145 creator A5007815174 @default.
• W2953732145 creator A5010147664 @default.
• W2953732145 creator A5013032650 @default.
• W2953732145 creator A5022971416 @default.
• W2953732145 creator A5035191354 @default.
• W2953732145 creator A5038633732 @default.
• W2953732145 creator A5055605804 @default.
• W2953732145 creator A5060651306 @default.
• W2953732145 creator A5079512093 @default.
• W2953732145 creator A5080823169 @default.
• W2953732145 date "1991-02-14" @default.
• W2953732145 modified "2023-10-12" @default.
• W2953732145 title "A Controlled Trial Comparing Vidarabine with Acyclovir in Neonatal Herpes Simplex Virus Infection" @default.
• W2953732145 cites W1515503939 @default.
• W2953732145 cites W1796276420 @default.
• W2953732145 cites W1934613443 @default.
• W2953732145 cites W2020277249 @default.
• W2953732145 cites W202635507 @default.
• W2953732145 cites W2031783599 @default.
• W2953732145 cites W2045360603 @default.
• W2953732145 cites W2047415999 @default.
• W2953732145 cites W2062604147 @default.
• W2953732145 cites W2075104625 @default.
• W2953732145 cites W2076110701 @default.
• W2953732145 cites W2336900894 @default.
• W2953732145 cites W2594055767 @default.
• W2953732145 doi "https://doi.org/10.1056/nejm199102143240703" @default.
• W2953732145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1988829" @default.
• W2953732145 hasPublicationYear "1991" @default.
• W2953732145 type Work @default.
• W2953732145 sameAs 2953732145 @default.
• W2953732145 citedByCount "346" @default.
• W2953732145 countsByYear W29537321452012 @default.
• W2953732145 countsByYear W29537321452013 @default.
• W2953732145 countsByYear W29537321452014 @default.
• W2953732145 countsByYear W29537321452015 @default.
• W2953732145 countsByYear W29537321452016 @default.
• W2953732145 countsByYear W29537321452017 @default.
• W2953732145 countsByYear W29537321452018 @default.
• W2953732145 countsByYear W29537321452019 @default.
• W2953732145 countsByYear W29537321452020 @default.
• W2953732145 countsByYear W29537321452021 @default.
• W2953732145 countsByYear W29537321452022 @default.
• W2953732145 countsByYear W29537321452023 @default.
• W2953732145 crossrefType "journal-article" @default.
• W2953732145 hasAuthorship W2953732145A5007815174 @default.
• W2953732145 hasAuthorship W2953732145A5010147664 @default.
• W2953732145 hasAuthorship W2953732145A5013032650 @default.
• W2953732145 hasAuthorship W2953732145A5022971416 @default.
• W2953732145 hasAuthorship W2953732145A5035191354 @default.
• W2953732145 hasAuthorship W2953732145A5038633732 @default.
• W2953732145 hasAuthorship W2953732145A5055605804 @default.
• W2953732145 hasAuthorship W2953732145A5060651306 @default.
• W2953732145 hasAuthorship W2953732145A5079512093 @default.
• W2953732145 hasAuthorship W2953732145A5080823169 @default.
• W2953732145 hasBestOaLocation W29537321451 @default.
• W2953732145 hasConcept C141071460 @default.
• W2953732145 hasConcept C159047783 @default.
• W2953732145 hasConcept C187212893 @default.
• W2953732145 hasConcept C2522874641 @default.
• W2953732145 hasConcept C2776694085 @default.
• W2953732145 hasConcept C2776755627 @default.
• W2953732145 hasConcept C2778779478 @default.
• W2953732145 hasConcept C2779263901 @default.
• W2953732145 hasConcept C2781196997 @default.
• W2953732145 hasConcept C71924100 @default.
• W2953732145 hasConcept C83455156 @default.
• W2953732145 hasConceptScore W2953732145C141071460 @default.
• W2953732145 hasConceptScore W2953732145C159047783 @default.
• W2953732145 hasConceptScore W2953732145C187212893 @default.
• W2953732145 hasConceptScore W2953732145C2522874641 @default.
• W2953732145 hasConceptScore W2953732145C2776694085 @default.
• W2953732145 hasConceptScore W2953732145C2776755627 @default.
• W2953732145 hasConceptScore W2953732145C2778779478 @default.
• W2953732145 hasConceptScore W2953732145C2779263901 @default.
• W2953732145 hasConceptScore W2953732145C2781196997 @default.
• W2953732145 hasConceptScore W2953732145C71924100 @default.
• W2953732145 hasConceptScore W2953732145C83455156 @default.
• W2953732145 hasIssue "7" @default.
• W2953732145 hasLocation W29537321451 @default.
• W2953732145 hasLocation W29537321452 @default.
• W2953732145 hasOpenAccess W2953732145 @default.
• W2953732145 hasPrimaryLocation W29537321451 @default.
• W2953732145 hasRelatedWork W1562336285 @default.
• W2953732145 hasRelatedWork W1974535633 @default.
• W2953732145 hasRelatedWork W1989098265 @default.
• W2953732145 hasRelatedWork W2014516093 @default.
• W2953732145 hasRelatedWork W2050841599 @default.
• W2953732145 hasRelatedWork W2060180761 @default.
• W2953732145 hasRelatedWork W2074001197 @default.
• W2953732145 hasRelatedWork W2105327147 @default.
• W2953732145 hasRelatedWork W2167034769 @default.
• W2953732145 hasRelatedWork W2416116653 @default.
• W2953732145 hasVolume "324" @default.
• W2953732145 isParatext "false" @default.
• W2953732145 isRetracted "false" @default.

• next